Bortezomib resistance in multiple myeloma is associated with increased serine synthesis.

Esther A ZaalWei WuGerrit JansenSonja ZweegmanJacqueline CloosCelia R Berkers

Published in: Cancer & metabolism (2017)

Our findings indicate that interfering with serine metabolism may be a novel strategy to improve bortezomib therapy and identify PHGDH as a potential biomarker for BTZ resistance.

Keyphrases

multiple myeloma
protein kinase
newly diagnosed
mesenchymal stem cells
cell therapy